Document Type
Article
Publication Date
11-21-2024
Abstract
Diffuse Large B-cell Lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma (NHL). Despite the use of newer agents, such as polatuzumab vedotin, more than one-third of patients have ultimately relapsed or experienced refractory disease. MiRNAs are single-stranded, ~22-nucleotide-long RNAs that interact with their target RNA. They are significant regulators of post-transcriptional gene expression. One significant miRNA, miR-155, is involved in the pathophysiology of DLBCL and it is a critical modulator of hematopoiesis, inflammation, and immune responses. Targets of miR-155, such as histone deacetylase 4 (HDAC4), suppressor of cytokine signaling-1 (SOCS1) and immune cells, play a crucial role in DLBCL pathogenesis, since miR-155 regulates key pathways, transcription factors and cytokine expression and shapes the tumor microenvironment in DLBCL. In this review, we examine the role of miR-155 in DLBCL and its potential as a future diagnostic, prognostic, or predictive biomarker.
Recommended Citation
Koumpis, Epameinondas; Georgoulis, Vasileios; Papathanasiou, Konstantina; Papoudou-Bai, Alexandra; Kanavaros, Panagiotis; Kolettas, Evangelos; and Hatzimichael, Eleftheria, "The Role of microRNA-155 as a Biomarker in Diffuse Large B-Cell Lymphoma" (2024). Computational Medicine Center Faculty Papers. Paper 59.
https://jdc.jefferson.edu/tjucompmedctrfp/59
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
PubMed ID
39767565
Language
English
Comments
This article is the author's final published version in Biomedicines, Volume 12, Issue 12, December 2024, Article number 2658.
The published version is available at https://doi.org/10.3390/biomedicines12122658.
Copyright © 2024 by the authors.